As of May 31, 2026, the FDA reported 990+ adverse-event reports tied to compounded semaglutide and 730+ for other compounded GLP-1 products, citing risks from unapproved, non-sterile, or misbranded copycat products. The agency reiterated that compounded versions lack an FDA-approved-quality assurance.